OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) will present today positive results from its Phase 2b trial of TAK-861 in narcolepsy type 1 (NT1) as late-breaking data ...
High dose rezpegaldesleukin achieved statistical significance on multiple patient-reported outcome assessments at completion of 16-week induction period Interim data presented for patients who ...
ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy® (epinephrine nasal spray) ...
The Supreme Court of Georgia is testing out a new oral argument format in which parties are granted two minutes for uninterrupted opening arguments. Arguing before the Supreme Court of Georgia? Pack ...
SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...
Late-breaking oral presentation of interim safety and efficacy data from the phase 1 study of SBT-77-7101, including a favorable early safety profile, with preliminary clinical and mechanistic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback